Latest Non-coding RNA Stories
CRISPR, a system of genes that bacteria use to defend themselves against viruses, has been found to be involved in helping some bacteria evade the mammalian immune system. The results are scheduled for publication Sunday, April 14 in Nature. CRISPR is itself a sort of immune system for bacteria. Its function was discovered by dairy industry researchers seeking to prevent phages, the viruses that infect bacteria, from ruining the cultures used to make cheese and yogurt. Bacteria...
St. Jude Children's Research Hospital ties mutations in two genes to the death of motor neurons associated with ALS, or Lou Gehrig's disease, and other devastating neurodegenerative problems MEMPHIS, Tenn., March 3, 2013 /PRNewswire-USNewswire/ -- A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and related degenerative...
Links for disease and role in embryonic development Long segments of RNA— encoded in our DNA but not translated into protein—are key to physically manipulating DNA in order to activate certain genes, say researchers at The Wistar Institute. These non-coding RNA-activators (ncRNA-a) have a crucial role in turning genes on and off during early embryonic development, researchers say, and have also been connected with diseases, including some cancers, in adults. In an online article of...
As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention. Guest Editor Tom Cech, PhD and Executive Editor Fintan Steele, PhD explore the enormous potential value of this rapidly advancing research area in their Editorial " The (Noncoding) RNA World." The authors introduce a special research section on noncoding...
ST. LOUIS, Feb. 13, 2013 /PRNewswire/ -- Sigma-Aldrich((R)) Corporation (NASDAQ: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, through an exclusive collaboration with Drs. Hideo Iba and Takeshi Haraguchi at the University of Tokyo, released MISSION((R) )Synthetic and Lentiviral microRNA Inhibitors based upon the Tough Decoy (TuD) design for the long-term suppression of any miRNA endogenous to humans or mice. Custom designs for...
Non-coding RNA is essential for normal embryonic cardiogenesis Many different tissues and organs form from pluripotent stem cells during embryonic development. To date it had been known that these processes are controlled by transcription factors for specific tissues. Scientists from the Max Planck Institute for Molecular Genetics in Berlin, in collaboration with colleagues at MIT and the Broad Institute in Boston, have now been able to demonstrate that RNA molecules, which do not act as...
Scripps Research Institute Scientists at The Scripps Research Institute (TSRI) have made a major advance in understanding how flu viruses replicate within infected cells. The researchers used cutting-edge molecular biology and electron-microscopy techniques to "see" one of influenza's essential protein complexes in unprecedented detail. The images generated in the study show flu virus proteins in the act of self-replication, highlighting the virus's vulnerabilities that are sure to be of...
TUBINGEN, Germany, Sept. 18, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, today announced the completion of an EUR80 million financing round with its main investor, dievini Hopp BioTech Holding. In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC),...
LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development. These targets are focused on cardiovascular and metabolic diseases and...
(Ivanhoe Newswire) – A new study opens doors to understanding prostate cancer with the identification of a potential new pathway in prostate cancer cells by which cancer-driving gene products can be created. "Our work shows that cancers have many more tricks than we thought to generate potential cancer-driving genes or gene products," Hui Li, Ph.D., assistant professor of pathology at the University of Virginia in Charlottesville, and a recipient of an Innovative Research Grant from...
